Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The role of autologous transplantation in young and fit patients with multiple myeloma in 2022

Mohamad Mohty • 25 Aug 2022
IMS 2022
Multiple Myeloma
DETERMINATION

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, comments on the role of autologous hematopoietic stem cell transplantation (autoHSCT) in the treatment of young and fit patients with multiple myeloma in the era of novel immunotherapeutic agents. Prof. Mohty argues that the Phase III DETERMINATION study (NCT01208662) confirmed the role of autoHSCT as a standard of care in this patient population. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Mohamad Mohty

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals